Joseph Rimando

5PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Transplantation immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 20, 2026
Absolute risk trade-offs of donor age, sex, and graft source in PTCy-based transplantation.

|Feb 04, 2026
A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT.

Muhammad Umair Mushtaq, John F DiPersio, Jacques Azzi

|Oct 23, 2025
Remission of TP53-Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33).

Guenther Koehne, Muhammad U Mushtaq, Lori S Muffly

|Apr 11, 2022
How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond.

Joseph Rimando, Shannon R McCurdy, Leo Luznik

|Dec 20, 2018
HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Joseph Rimando, Michael Slade, John F DiPersio

Pageof 1

Frequent Collaborators

2 joint publications

Lori S Muffly

2 joint publications

Joseph Maakaron

2 joint publications

Jennifer S Whangbo

2 joint publications

Nirali N Shah